View Document Preview and Link Document Date: 2013-10-03 14:58:46 Open Document File Size: 86,00 KB Share Result on Facebook
City South San Francisco / New Orleans / Cambridge / / Company Elan Pharmaceuticals / Biogen Inc. / Canadian Multiple Sclerosis Working Group / / Country United States / / IndustryTerm treatment of multiple sclerosis / treatment of MS / magnetic resonance imaging / healthcare / / MedicalCondition disease / recurrent and progressive neurologic dysfunction / optic neuritis / vertigo / chronic demyelinating disease / fatigue / multiple sclerosis / MS / depression / ataxia / sensory loss / / Organization Sclerosis Society / American Academy of Neurology / MS Council for Clinical Practice Guidelines / FDA / Therapeutics and Technology Assessment Subcommittee / National Multiple Sclerosis Society / National Clinical Advisory Board / / / Position physician / neurologist / / Product Copaxone / The medication / Tysabri / Rebif / Betaseron / Avonex / / ProvinceOrState Mississippi / Louisiana / / Technology magnetic resonance imaging / MRI / / URL http / SocialTag 
To Initiate a Coverage Review, Call[removed]PRIOR AUTHORIZATION POLICY SUBJECT: Avonex® (interferon beta-1a, intramuscular